医学
免疫系统
免疫疗法
免疫检查点
梅德林
肿瘤科
无容量
内科学
癌症研究
免疫学
PD-L1
抗体疗法
肿瘤免疫学
癌症免疫疗法
临床试验
生物信息学
彭布罗利珠单抗
作者
Yuan Wu,Jianing Qin,Xin Jin,Yu Qian
出处
期刊:iScience
[Cell Press]
日期:2026-10-21
卷期号:29 (11): 117685-117685
标识
DOI:10.1016/j.isci.2026.117685
摘要
Several studies have reported that low-dose of programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors is effective. However, it is unknown whether the efficacy of low dose is as effective as standard dose. We compared the efficacy of PD-1/PD-L1 inhibitor at different doses as a single agent for patients with solid tumors. We searched published clinical trials with the clinical outcomes of PD-1/PD-L1 inhibitor until December 1, 2024. The low dose is defined as lower than the dose approved by FDA. A total of 1,084 patients from 14 studies were included in the analysis. The pooled analysis of seven studies demonstrated no significant difference in overall survival (OS) between the low dose and standard dose of PD-1/PD-L1 inhibitor. Safety evaluations from five studies indicated no significant differences in adverse events (AEs). Our study indicated that low dose of PD-1/PD-L1 inhibitor as monotherapy can provide comparable efficacy and safety to standard dose in patients with solid tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI